The present invention provides a protein aggregation inhibitor for use in preventing aggregation of a protein, containing a crosslinked polymer obtained by polymerizing polymerizable polymer components containing a sulfobetaine polymer obtained by polymerizing monomer components containing a sulfobetaine monomer, the sulfobetaine monomer, and a crosslinkable monomer.

Systems and methods for modeling a three-dimensional protein structure are disclosed. The method includes receiving a primary amino acid sequence of a three-dimensional protein, translating the primary amino acid sequence to a first vector, determining a per-residue conformation index for each amino acid residue in the primary amino acid sequence, determining a vector set for each amino acid residue in the primary amino acid sequence, and using the per-residue interaction vector set to generate a multi-dimensional matrix for the three-dimensional protein structure. The first vector includes a unique numerical descriptor value corresponding to each amino acid residue in the primary amino acid sequence. The vector set includes a plurality per-residue interaction factors corresponding to a plurality of conformation indexes for that amino acid residue.

Provided are a novel polypeptide having endolysin activity, a fusion protein comprising the polypeptide and an antibiotic active protein, and an antibiotic use against a gram-negative pathogen of the polypeptide and/or fusion protein and/or a use for prevention and/or treatment of gram-negative pathogen infection and/or disease or symptoms related to gram negative pathogen infection.

The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.

Provided are a novel polypeptide, a fusion polypeptide comprising the polypeptide, and a use thereof as an antibiotic. More specifically, provided are a novel polypeptide derived from a bacteriophage, a novel fusion polypeptide comprising cecropin A, and an antibiotic against Gram-negative bacteria comprising the polypeptide and/or the fusion polypeptide.

Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, and low molecular weight aliphatic polyacids, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.

Multiblock polymer materials, methods of preparing, and using to separate proteins, nucleic acids, other biological or other biomolecules, compounds, or solutes, with high fluxes through electrostatic interactions where the self-assembled block polymer materials contain at least one of macro, meso, or micro pores, and at least some of the pores are isoporous, and at least one polymer block contains stationary electrostatic charge, or reactive functional groups to provide large surface areas that are charged in isoporous structure.

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

The present invention relates to new species-selective phage endolysins and their use to treat bacterial vaginosis (BV). The present invention provides recombinant endolysins, i.e. domain-swapped endolysins. The invention also relates to said endolysins for use in treating diseases or disorders such as bacterial infections, in particular BV. The invention further relates to polynucleotides encoding said endolysins. Said polynucleotides can also be used for treating such diseases or disorders. Also provided by the present invention is a pharmaceutical composition comprising an endolysin of the invention for use in treating such diseases or disorders. Said endolysins, polynucleotides and pharmaceutical composition may be administered locally, in particular locally into the vagina.

Provided is a protein derived from Tumebacillus sp. NITE BP-02779 and having peptidoglycan-degrading activity. Provided is a protein comprising the amino acid sequence at positions 1 to 164 of SEQ ID NO: 2 or the amino acid sequence at positions 1 to 493 of SEQ ID NO: 4, or the amino acid sequences with a substitution, deletion, insertion, or addition of 1 to 10 amino acid residues, or an amino acid sequence having 90% or more identity to the amino acid sequences, and having peptidoglycan-degrading activity.